Business
Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology
SOPHIA ANTIPOLIS, France, March 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer diagnosis and a global leader in AI-based image analysis and central imaging services for oncology drug development, today announced that it will feature eyonis® LCS at the European Congress of Radiology (ECR) 2026 in Vienna, March 4–6, 2026.
About this update from Median Technologies
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/baebabf3c3f4b99b61df22b02556b78c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.oYSG_nqB43ZjbFRVKwIIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/baebabf3c3f4b99b61df22b02556b78c","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fKi4eteZjsphqSHWLa7N9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/baebabf3c3f4b99b61df22b02556b78c","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"eyonis® LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance","length":79,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CE-marking regulatory process is on-going with a decision expected in Q2 2026 that could trigger commercial rollout of eyonis® LCS across Europe this year","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Median eyonis® team will be at Booth #AI-16, AI Exhibition, Expo X1, to highlight clinical impact of eyonis® LCS in lung cancer screening","length":137,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"eyonis® LCS will also be featured in two AI Lightning Talk industry sessions and one research session","length":101,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":471,"olType":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, March 02, 2026--(BUSINESS WIRE)--Regulatory News:","length":75,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer diagnosis and a global leader in AI-based image analysis and central imaging services for oncology drug development, today announced that it will feature eyonis® LCS at the European Congress of Radiology (ECR) 2026 in Vienna, March 4–6, 2026.","length":455,"tagName":"p"},{"type":"text","content":"The Median eyonis® team will welcome attendees at Booth #AI-16, AI Exhibition, Expo X1, from March 4 to March ...